Medinotec's Revenue Soars 76% Amidst Rising Operating Costs

TL;DR

**MDNC is growing revenue fast, but watch those soaring expenses – it's a high-risk, high-reward play.**

AI Summary

Medinotec Inc. reported significant revenue growth for the six months ended August 31, 2025, reaching $5,370,331, a substantial increase from $3,055,897 in the prior year period. Net income also rose to $460,350 for the six-month period, up from $371,953 in the same period last year. The company's gross profit nearly doubled to $2,927,504 from $1,433,690 year-over-year. Operating expenses, however, saw a considerable jump, with sales and marketing expenses increasing to $696,177 from $43,451, and general and administrative expenses rising to $1,295,053 from $631,014. Cash and cash equivalents decreased by $521,591 to $2,248,095 as of August 31, 2025, primarily due to significant debt repayments of $980,467. The company, primarily invested in South African medical device manufacturer DISA Medinotec, aims to expand its U.S. market presence, leveraging its FDA 510(k) approval for the Trachealator. Foreign currency translation adjustments resulted in a $2,819 loss in other comprehensive income for the six months ended August 31, 2025.

Why It Matters

Medinotec's strong revenue growth of 75.7% and increased net income signal robust operational performance, which could attract new investors looking for growth in the medical device sector. However, the significant increase in operating expenses, particularly sales and marketing, suggests the company is aggressively investing in expansion, which could impact future profitability if not managed effectively. For employees, this growth could mean more opportunities, especially with the planned U.S. market expansion. Customers could benefit from increased product availability, particularly the Trachealator in the U.S. market, intensifying competition with existing medical device players.

Risk Assessment

Risk Level: medium — The company exhibits medium risk due to its significant reliance on South African operations and exposure to currency volatility, as noted by 'the emerging market nature of this currency the spread volatility of the currency low and high can be material during a year.' While revenue is growing, operating expenses, particularly sales and marketing, have surged from $43,451 to $696,177, indicating aggressive spending that could strain cash flow, which decreased by $521,591.

Analyst Insight

Investors should monitor Medinotec's upcoming earnings reports closely to assess if the substantial increase in sales and marketing expenses translates into sustainable U.S. market penetration and improved profitability. Consider holding if you believe in their U.S. expansion strategy, but be prepared for potential volatility due to foreign currency exposure and high operational burn.

Financial Highlights

debt To Equity

0.30

revenue

$5.37M

operating Margin

26.7%

total Assets

$6.37M

total Debt

$0.44M

net Income

$460,350

eps

$0.04

gross Margin

54.5%

cash Position

$2.25M

revenue Growth

+75.7%

Key Numbers

• $5.37M — Revenue (Increased from $3.06M for the six months ended August 31, 2024)
• $460,350 — Net Income (Increased from $371,953 for the six months ended August 31, 2024)
• $2.93M — Gross Profit (Increased from $1.43M for the six months ended August 31, 2024)
• $696,177 — Sales and Marketing Expenses (Increased from $43,451 for the six months ended August 31, 2024)
• $1.30M — General and Administrative Expenses (Increased from $631,014 for the six months ended August 31, 2024)
• $2.25M — Cash and Cash Equivalents (Decreased from $2.77M as of February 28, 2025)
• $980,467 — Repayment of Debt (Cash outflow from financing activities for the six months ended August 31, 2025)
• 11,755,548 — Common Shares Outstanding (As of October 8, 2025)
• $0.04 — Basic Earnings Per Share (For the six months ended August 31, 2025, up from $0.03)
• 75.7% — Revenue Growth (Percentage increase for the six months ended August 31, 2025, compared to the prior year)

Key Players & Entities

• Medinotec Inc. (company) — registrant
• DISA Medinotec Proprietary Limited (company) — South African subsidiary
• Medinotec Capital Proprietary Limited (company) — wholly owned subsidiary
• Trachealator (product) — flagship product with FDA 510(k) approval
• SEC (regulator) — Securities and Exchange Commission
• OTCQX (market) — exchange where MDNC trades
• FASB ASC 326 (standard) — Measurement of Credit Losses on Financial Instruments
• Sarbanes-Oxley Act (regulation) — auditor attestation requirements
• Jumpstart our Business Startups Act of 2012 (regulation) — JOBS Act
• United States (country) — primary investment location

FAQ

Risk Factors

• FDA Approval Dependency [high — regulatory]: The company's expansion into the U.S. market is contingent on its FDA 510(k) approval for the Trachealator. Any delays, challenges, or changes in regulatory requirements could significantly impede market penetration and revenue generation.
• Cash Burn and Debt Repayment [medium — financial]: Cash and cash equivalents decreased by $521,591 to $2,248,095 as of August 31, 2025, largely due to a significant debt repayment of $980,467. While reducing debt is positive, the substantial outflow impacted liquidity, requiring careful cash flow management.
• Significant Increase in Operating Expenses [medium — operational]: Sales and marketing expenses surged to $696,177 from $43,451, and G&A expenses rose to $1,295,053 from $631,014 year-over-year for the six-month period. This rapid escalation in operating costs, while potentially supporting growth initiatives, needs to be monitored to ensure it aligns with revenue generation and profitability.
• Foreign Currency Fluctuations [low — financial]: The company experienced a $2,819 loss in other comprehensive income due to foreign currency translation adjustments for the six months ended August 31, 2025. As Medinotec is invested in a South African manufacturer, ongoing currency volatility could impact reported earnings.

Industry Context

Medinotec operates within the medical device manufacturing sector, which is characterized by rigorous regulatory oversight, significant R&D investment, and a competitive landscape. The company's focus on specialized respiratory devices, like the Trachealator, positions it within a niche segment. Success hinges on technological innovation, FDA approvals, and effective market penetration strategies, particularly in expanding into new geographic markets like the U.S.

Regulatory Implications

The company's primary regulatory hurdle is obtaining and maintaining FDA 510(k) approval for its key products, such as the Trachealator, to access the lucrative U.S. market. Compliance with evolving medical device regulations in both the U.S. and South Africa is critical to avoid penalties and ensure continued market access.

What Investors Should Do

1. Monitor operating expense growth relative to revenue.
2. Evaluate the cash flow generation and liquidity position.
3. Assess the progress and timeline for U.S. market expansion.
4. Analyze the impact of foreign currency fluctuations.

Key Dates

• 2025-08-31: Six months ended August 31, 2025 — Period of significant revenue growth and increased operating expenses, with substantial debt repayment impacting cash reserves.
• 2025-02-28: February 28, 2025 — Previous balance sheet date, showing higher cash and cash equivalents ($2.77M) and higher total liabilities ($2.54M) compared to August 31, 2025.
• 2024-08-31: Six months ended August 31, 2024 — Prior year period for comparison, showing lower revenue ($3.06M) and net income ($371,953), with significantly lower operating expenses.
• 2025-10-08: Common Shares Outstanding — As of this date, there were 11,755,548 common shares outstanding, relevant for per-share calculations.

Glossary

FDA 510(k) approval

A premarket submission made to the U.S. Food and Drug Administration (FDA) to demonstrate that a new medical device is safe and effective, substantially equivalent to a legally marketed device. (Crucial for Medinotec's strategy to expand its U.S. market presence with its Trachealator product.)

Other comprehensive income/(loss)

Includes gains and losses that are not recognized in net income on the income statement but are reported in a separate section of the income statement or on the balance sheet. Common items include foreign currency translation adjustments. (Shows a $2,819 loss for Medinotec due to foreign currency translation, impacting overall equity.)

Operating right-of-use asset

An asset recognized under lease accounting standards representing the lessee's right to use an underlying asset for the lease term. (Represents a small portion of Medinotec's assets, decreasing slightly from $37,301 to $25,542.)

Accumulated other comprehensive income

The cumulative amount of other comprehensive income/(loss) recognized by a company over time. (Stands at $41,770 as of August 31, 2025, down from $44,589 at the prior balance sheet date.)

Deferred tax asset

A company's future tax benefit that results from temporary differences between the book and tax bases of assets and liabilities, or from operating loss or tax credit carryforwards. (Appeared on the balance sheet as of August 31, 2025, with a value of $34,366, whereas it was zero at the prior balance sheet date.)

Year-Over-Year Comparison

Medinotec Inc. has demonstrated robust top-line growth, with revenue increasing by 75.7% to $5.37M for the six months ended August 31, 2025, compared to the prior year. This growth translated into a higher gross profit of $2.93M. However, operating expenses, particularly sales and marketing and general and administrative costs, have surged dramatically, indicating significant investment in expansion. While net income and EPS have improved, the substantial increase in operating expenses warrants close attention. The company's cash position has decreased due to debt repayment, and it continues to navigate foreign currency translation impacts.

Key Financial Figures

• $3 million — lity of a private placement of at least $3 million. This acquisition formed the "Medinotec

Filing Documents

• mdnc10q2_083125.htm (10-Q) — 970KB
• image_001.jpg (GRAPHIC) — 5KB
• ex31_1.htm (EX-31.1) — 9KB
• ex31_2.htm (EX-31.2) — 9KB
• ex32_1.htm (EX-32.1) — 5KB
• 0001663577-25-000293.txt ( ) — 4987KB
• mdnc-20250831.xsd (EX-101.SCH) — 32KB
• mdnc-20250831_cal.xml (EX-101.CAL) — 50KB
• mdnc-20250831_def.xml (EX-101.DEF) — 99KB
• mdnc-20250831_lab.xml (EX-101.LAB) — 232KB
• mdnc-20250831_pre.xml (EX-101.PRE) — 212KB
• mdnc10q2_083125_htm.xml (XML) — 900KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1: Consolidated Financial Statements (unaudited for period ended August 31, 2025) 3 Item 2:

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 4 Item 3:

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 18 Item 4:

Controls and Procedures

Controls and Procedures 18

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1:

Legal Proceedings

Legal Proceedings 19 Item 1A:

Risk Factors

Risk Factors 19 Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 19 Item 3: Defaults Upon Senior Securities 19 Item 4: Mine Safety Disclosure 19 Item 5: Other Information 19 Item 6: Exhibits 20 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Consolidated Financial Statements

Item 1. Consolidated Financial Statements Our unaudited consolidated financial statements included in this Form 10-Q are as follows: Page Number F-1 Unaudited Consolidated Balance Sheets as of August 31, 2025 and February 28, 2025; F-2 Unaudited Consolidated Statements of Operations and Comprehensive Income/(Loss) for the three and six months ended August 31, 2025 and August 31, 2024; F-3 Unaudited Consolidated Statements of Stockholders' Equity / (Deficit) for the three and six months ended August 31, 2025 and August 31, 2024; F-4 Unaudited Consolidated Statements of Cash Flows for the six months ended August 31, 2025 and August 31, 2024; and F-5 Notes to the Unaudited Consolidated Financial Statements. 3 Table of Contents Medinotec Incorporated Consolidated Financial Statements Consolidated Balance Sheets for the Medinotec Group of Companies as of August 31, 2025 and February 28, 2025 August 31, 2025 (Unaudited) $ February 28, 2025 $ Assets Current Assets Cash 2,248,095 2,769,686 Accounts receivable, net of allowances 2,575,271 2,612,440 Inventory 994,074 988,341 Other current assets 161,238 52,719 Total Current Assets 5,978,678 6,423,186 Notes receivable — — Property, plant and equipment, net of accumulated depreciation 333,296 348,486 Deferred tax asset 34,366 — Operating right-of-use asset 25,542 37,301 Total Assets $ 6,371,882 $ 6,808,973 Liabilities and Stockholders' Equity Current Liabilities Accounts payable and accrued liabilities 1,505,373 1,476,987 Operating lease liability, current portion 28,716 28,060 Total Current Liabilities 1,534,089 1,505,047 Long Term Liabilities Loans payable 443 940,277 Deferred tax liabilities — 80,124 Operating lease liability, net of current portion — 12,696 Total Liabilities 1,534,532 2,538,144 Stockholders' Equity Capital stock 11,756 11,734 Capital stock additional paid in capital 3,405,359 3,296,3

View Full Filing

View this 10-Q filing on SEC EDGAR